Yi-Xiao Geng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi-Xiao Geng has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Ai-Lian Du
Department of Neurology, Songjiang Hospital, Songjiang Research Institute, State Key Laboratory of Eye Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publicationChen-Xi Lin
College of Basic Medical Science, Shanghai Jiao Tong University School of medicine, Shanghai, China
1 shared publication- Fei Li
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China
1 shared publication Gong-Jia Tao
Department of Neurology, Songjiang Hospital, Songjiang Research Institute, State Key Laboratory of Eye Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publicationJia-Shuo Wen
School of Medicine, Yunnan University, Kunming, China
1 shared publicationJie Li
Institute of Pediatrics, National Children’s Medical Center, Children’s Hospital, Institute for Translational Brain Research, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 18 February 2026
- Published by Springer Nature in Nature
- Vol. 651 (8106) , 785-795
In vivo base editing of Chd3 rescues behavioural abnormalities in mice
Neurodevelopmental disorders that arise from de novo mutations in chromatin-remodelling genes lack targeted treatments. Snijders Blok–Campeau syndrome (SNIBCPS)1, which is caused by pathogenic variants in CHD3, manifests with intellectual disability, autistic-like behaviours and motor deficits2. Whether somatic gene correction can reverse such phenotypes in vivo remains unknown. Here we show that modelling the recurrent CHD3 variant p.R1025W in a humanized mouse model (Chd3hR1025W/+) recapitulates key features of SNIBCPS, including reduced CHD3 protein levels and abnormalities in social communication, cognition and motor coordination. We engineered a TadA-embedded adenine base editor (TeABE) and delivered it brain-wide using a dual adeno-associated virus (AAV) system and achieved efficient on-target A•T-to-G•C correction across multiple cortical and hippocampal regions with minimal bystander activity. This intervention restored CHD3 levels and ameliorated behavioural abnormalities in vivo. Furthermore, intrathecal dual AAV delivery in nonhuman primates resulted in widespread neuronal transduction and efficient TeABE reconstitution, a result that supports its translational feasibility. These findings establish in vivo base editing as a viable therapeutic approach for CHD3-related neurodevelopmental disease. More broadly, they demonstrate that precise single-base correction in the postnatal brain can restore protein dosage and function, thereby offering a framework for the treatment of monogenic neurodevelopmental disorders.
- 18 February 2026
- Published by Springer Nature in Nature
- Vol. 651 (8106) , 785-795
Top Cited PapersOpen AccessIn vivo base editing of Chd3 rescues behavioural abnormalities in mice
Neurodevelopmental disorders that arise from de novo mutations in chromatin-remodelling genes lack targeted treatments. Snijders Blok–Campeau syndrome (SNIBCPS)1, which is caused by pathogenic variants in CHD3, manifests with intellectual disability, autistic-like behaviours and motor deficits2. Whether somatic gene correction can reverse such phenotypes in vivo remains unknown. Here we show that modelling the recurrent CHD3 variant p.R1025W in a humanized mouse model (Chd3hR1025W/+) recapitulates key features of SNIBCPS, including reduced CHD3 protein levels and abnormalities in social communication, cognition and motor coordination. We engineered a TadA-embedded adenine base editor (TeABE) and delivered it brain-wide using a dual adeno-associated virus (AAV) system and achieved efficient on-target A•T-to-G•C correction across multiple cortical and hippocampal regions with minimal bystander activity. This intervention restored CHD3 levels and ameliorated behavioural abnormalities in vivo. Furthermore, intrathecal dual AAV delivery in nonhuman primates resulted in widespread neuronal transduction and efficient TeABE reconstitution, a result that supports its translational feasibility. These findings establish in vivo base editing as a viable therapeutic approach for CHD3-related neurodevelopmental disease. More broadly, they demonstrate that precise single-base correction in the postnatal brain can restore protein dosage and function, thereby offering a framework for the treatment of monogenic neurodevelopmental disorders.